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Introduction
Accumulation of amyloid β (Aβ) peptides in senile plaques 
in the cerebral cortex is an early event in the pathogenesis 
of Alzheimer disease (AD) [1]. e longest isoform of Aβ, 
consisting of 42 amino acids (Aβ1-42), is produced from 
amyloid precursor protein (APP) by sequen tial cleavage by 
β- and γ-secretase in the amyloido genic APP-processing 
pathway (Figure 1A) [2]. β-Secretase activity originates 
from an integral membrane aspartyl protease encoded by 
the β-site APP-cleaving enzyme 1 gene (BACE1) [3-6] 
whereas γ-secretase is an intramembrane-cleaving 
complex composed of at least four essential subunits with 
the presenilin (PS1 or PS2) proteins at its enzymatic core 
[7-9]. γ-Secretase, which is one of the top targets for 
developing AD therapeutics with disease-modifying 
effects, cleaves the transmembrane region of APP to 
produce Aβ of variable length [10-12], with Aβ1-40 being 
the most abundant isoform, whereas Aβ1-42 is most 
prone to aggregation [13-14].
e main focus of using disease-modifying drugs is to 
inhibit brain Aβ production and aggregation and to 
increase Aβ clearance from the brain. Several drug 
candidates, including β-secretase and γ-secretase inhibi-
tors or Aβ immunotherapy, are being evaluated in 
different phases in clinical trials. However, in a slowly 
progressive disorder like AD, evaluation of the clinical 
effect of a disease-modifying drug by using rating scales 
requires large patient numbers and extended treatment 
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periods. This type of drug cannot be expected to have any 
early effect on symptoms, but instead may show a less-
pronounced decline in cognitive function over years. 
Thus, a great need exists for biomarkers to identify and 
monitor the biochemical effect of disease-modifying 
drugs in AD clinical trials. Such biomarker data providing 
evidence directly in patients with AD that the drug has 
the predicted mechanism of action may be valuable for 
making a go/no-go decision for large and expensive 
Phase II or III clinical trials.
In animal studies, a decrease in soluble Aβ levels and 
Aβ accumulation has been reported in response to γ-
secretase inhibition [15-18]. Recently, in a human clinical 
trial, it was shown, by using enzyme-linked immuno-
sorbent assay (ELISA), that the γ-secretase inhibitor 
LY450139 reduces the concentration of Aβ1-40 and 
Aβ1-42 in human plasma in a dose-dependent manner, 
where as a significant decrease in human cerebrospinal 
fluid (CSF) Aβ levels was not detected [19]. However, by 
using a stable isotope-labeling kinetic (SILK) method, 
which can be used to measure central nervous system 
(CNS) production and clearance rates of total Aβ in the 
CSF of humans [20], it was shown that LY450139 
significantly decreased Aβ production without affecting 
Aβ clearance in the CNS [21].
We recently identified a set of 18 N- and C-terminally 
truncated Aβ peptides in human CSF by using immuno-
precipitation-mass spectrometry (IP-MS) and showed 
that CSF Aβ1-16 may be a novel positive biomarker for 
AD that was elevated in AD patients [22]. This novel 
biomarker for AD is generated through a previously 
unrecognized metabolic pathway by concerted β- and α-
secretase cleavage of APP (Figure 1B) [23]. Further, the 
relative level of Aβ1-16, along with Aβ1-14 and Aβ1-15, 
has previously been shown to be elevated in cell media 
and in CSF from mice in response to γ-secretase inhibitor 
Figure 1. Schematic drawing of APP and generation of Aβ isoforms. The 17-amino acid signal peptide is indicated at the N-terminus. A single 
membrane-spanning domain is located at amino acids 700-723 in the longest APP isoform (APP770). (a) In the amyloidogenic pathway, β-secretase 
cleaves after residue 671, generating β-sAPP, which is secreted, and a C-terminal fragment (β-CTF or C99), which is retained in the membrane. The 
β-CTF fragment can undergo further cleavage by γ-secretase to release Aβ isoforms. (b) In another pathway, APP is first cleaved by β-secretase, 
but after this, by α-secretase, thus generating the shorter isoforms Aβ1-14, Aβ1-15, and Aβ-16. In another described nonamyloidogenic pathway, 
α-secretase cleaves between amino acids 16 and 17 in the Aβ sequence generating α-sAPP, followed by γ-secretase cleavages, generating a 
fragment called p3 (Aβ17-40/42). This 3-kDa fragment has been isolated from cell-culture medium [29] and in brains from AD patients [30]. 
However, the fragment has never been detected in human CSF. AICD, APP intracellular domain; APP, amyloid precursor protein; Aβ, amyloid β; sAPP, 
soluble amyloid precursor protein.
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treatment [23,24], suggesting that these shorter Aβ 
isoforms may be sensitive biomarkers for γ-secretase 
inhibitor treatment. Here, we tested the hypothesis that 
treatment of AD patients with the γ-secretase inhibitor 
LY450139 can be monitored by increased CSF levels of 
Aβ1-14, Aβ1-15, and Aβ1-16.
Materials and methods
Study participants and sample collection
The study cohort and clinical procedures have been 
described before in detail [19]. In brief, 51 patients were 
enrolled at six academic research centers between 
October 1, 2005, and December 31, 2006 (Figure 2a). The 
protocol was reviewed and approved by the institutional 
review board at each participating site. All research 
participants and caregivers gave written informed 
consent. Of the 51 patients enrolled in the study, CSF 
samples from 35 patients were available for analysis by 
IP-MS. See Table 1 for demographic data.
Participants were 50 years or older and diagnosed as 
having probable AD, as defined by the National Institute 
of Neurological and Communicative Disorders and 
Stroke and the Alzheimer Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria [25]. Individuals 
receiving stable doses of cholinesterase-inhibitor drugs 
or memantine were included. The trial was a multicenter, 
randomized, double-blind, placebo-controlled, dose-
escalation study (Figure 2a). Participants were random ized 
to receive LY450139 or placebo by using a 2:1 randomi-
zation scheme through a telephone-based inter active 
voice-response system (Figure 2b). Patients ran dom ized to 
the LY450139 groups received 60 mg/d for 2  weeks, and 
then 100 mg/d for the next 6 weeks. At 8  weeks, the 
treatment arm was randomized again to receive 6 addi-
tional weeks of treatment at 100 or 140 mg/d.
The CSF samples were collected into polypropylene 
tubes by means of a lumbar puncture at baseline and 
approximately 6 hours after the administration of the last 
dose of LY450139 at week 14.
APP measurements
CSF concentrations of α-secretase-cleaved soluble APP 
(α-sAPP) and β-secretase-cleaved soluble APP (β-sAPP) 
were determined by using the MSD sAPPα/sAPPβ 
multiplex assay, as described by the manufacturer (Meso 
Scale Discovery, Gaithersburg, MD, USA). This assay 
uses the 6E10 antibody to capture α-sAPP and a 
neoepitope-specific antibody to capture β-sAPP. Both 
isoforms are detected by the SULFO-TAG-labeled anti-
APP antibody p2-1.
IP-MS
IP was combined with matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) MS for analyzing 
the Aβ isoform pattern in a single analysis. The IP-MS 
was conducted as described before [26]. In brief, 8 mg of 
the monoclonal antibody 6E10 (Aβ epitope 4–9; Signet 
Laboratories, Inc., Dedham, MA, USA) was added to 
50 ml Dynabeads M-280 (Dynal) sheep anti-mouse and 
left overnight on a rocking platform (+4°C). The IP was 
conducted overnight (+4°C) on 940 ml CSF, to which 
10  ml 2.5% Tween-20 (Bio-Rad Laboratories, Inc.) had 
been added. The beads/CSF solution (total volume, 1 ml) 
was transferred to a KingFisher magnetic particle proces-
sor (polypropylene tubes; Thermo Scientific) for washing 
and elution in a five-step procedure. The collected 
Figure 2. Data flowchart for the trial. (a) The intention-to-treat 
analyses included all 51 patients originally randomized, including all 
subsequent dropouts. Of the 51 patients, 35 were analyzed by using 
IP-MS. (b) Study design.
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supernatant was dried in a vacuum centrifuge and 
redissolved in 5 ml 0.1% formic acid in 20% acetonitrile.
The samples were analyzed with MALDI-TOFMS 
(Autoflex, Bruker Daltonics, Bremen, Germany) operat-
ing in reflector mode. The acquired MS data were anal-
yzed by the software Medicwave Bioinformatics Suite 
(MBS) by using the immunoprecipitation for MALDI 
(IPM) module (MedicWave, Halmstad, Sweden) for 
automatic processing of the all spectra. In brief, after 
internal calibration, baseline subtraction, and smoothing, 
the peaks for each spectrum were integrated with the 
integration limits −2 to +5 m/z relative to the mono-
isotopic peak. Before the statistical analysis, the peak 
areas were normalized to the sum of the integrated peaks, 
duplicated samples were averaged, and the relative 
changes compared with baseline values were calculated, 
as described previously [22].
Group differences were analyzed by using the Kruskal-
Wallis test, and in case of significance (P < 0.05), followed 
by Mann-Whitney test to identify the differences.
Results
Representative CSF Aβ isoform mass spectra from an AD 
patient before treatment and after 14 weeks on the high 
dosage of the γ-secretase inhibitor LY450139 are shown 
in Figure 3a. The treatment greatly increased the mass 
spectrometric signal for Aβ1-14, Aβ1-15, and Aβ1-16, 
whereas the mass spectrometric signal corresponding to 
Aβ1-34 decreased as a response to treatment (Kruskal-
Wallis test, P = 0.009, 0.01, 0.05, and 0.000041, respec-
tively). The other Aβ isoforms reproducibly detected in 
all spectra (Aβ1-17, Aβ1-18, Aβ1-19, Aβ1-33, Aβ1-37, 
Aβ1-38, Aβ1-40, and Aβ1-42) did not differ significantly 
in intensity before and after treatment. The levels of the 
Aβ isoforms Aβ1-13 and Aβ1-20 were low, were not 
detected in all samples, and were therefore omitted from 
further analysis. The mass-to-charge (m/z) ratio of Aβ1-
18 [M + H]+ is almost identical to the m/z of the second 
charge state of Aβ1-40 [M + 2H]2+ and therefore difficult 
to quantify; it was excluded from further analysis.
In the 100-mg group, after drug administration at week 
14, the CSF levels of Aβ1-14, Aβ1-15, and Aβ1-16 were 
significantly increased by a mean of 57%, 21%, and 30%, 
respectively, whereas Aβ1-34 decreased 39% (see 
Figure 3b and Table 2) compared with study baseline. The 
same result was seen in the 140-mg group, Aβ1-14, 
Aβ1-15 and Aβ1-16 were increased by means of 74%, 
35%, and 67%, respectively, whereas Aβ1-34 decreased 
37% (Table 2). No statistically significant changes were 
seen for any other Aβ isoforms detected. α-sAPP showed 
a tendency to increased levels (13%) in the 140-mg group, 
whereas β-sAPP was unaffected by all the treatments 
(Figure 3c).
Discussion
Intense multidisciplinary research efforts during the last 
decades have provided detailed knowledge on the 
molecular pathogenesis of AD, which has been translated 
into novel promising therapies with putative disease-
modifying effects. Several promising drug candidates, 
such as Aβ immunotherapy and secretase inhibitors, are 
now being tested in clinical trials. However, because the 
predicted clinical effect of this type of disease-modifying 
drugs is a less-pronounced slope in the rate of cognitive 
deterioration, without any early symptomatologic effect, 
very large clinical trials with extended treatment periods 
will be needed to identify a beneficial clinical effect by 
using rating scales. Thus, biomarker evidence from 
smaller short-term clinical trials that the drug has the 
predicted biochemical mode of action directly in patients 
with AD would be valuable for making a go/no-go 
Table 1. Participant characteristics at baseline
Characteristic Placebo (n = 10) LY450139, 100 mg (n = 15) LY450139, 140 mg (n = 10)
Demographics
 Age, mean (SD, years) 69.1 (8.81) 72.4 (8.13) 68.8 (9.02)
 Female sex, number (%) 5 (50) 10 (66.6) 4 (40)
 APOE e4 carriers, number (%) 8 of 10 (80) 11 of 13 (84.6) 7 of 9 (77.8)
Clinical scores, mean (SD)
 MMSE 18.3 (4.0) 22 (3.6) 24.9 (1.4)
 ADCS-ADL 61.9 (7.3) 67.7 (8.4) 70.6 (7.8)
 ADAS-Cog 11 26.9 (10.0) 19.9 (6.3) 17.9 (5.8)
ADAS-Cog 11, Alzheimer’s Disease Assessment Scale Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale; APOE, 
apolipoprotein E; MMSE, Mini-Mental State Examination.
Table 2. Summary of Mann-Whitney test for peptides
 Placebo vs. 100 mg Placebo vs. 140 mg 100 mg vs. 140 mg
Aβ1-14 0.002 0.03 0.58
Aβ1-15 0.04 0.004 0.17
Aβ1-16 0.05 0.003 0.04
Aβ1-34 0.00005 0.0002 0.82
Kruskal-Wallace test, P < 0.05.
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decision for expensive Phase III clinical trials. Thus, a 
great need exists for biomarkers to identify and monitor 
the biochemical effect of disease-modifying drugs in AD 
clinical trials.
The main focus with disease-modifying drugs is to 
inhibit brain Aβ production and aggregation and to 
increase Aβ clearance from the brain. γ-Secretase inhibi-
tors have previously been shown to reduce Aβ1-40 and 
Aβ1-42 production and secretion in cells and to reduce 
soluble Aβ and amyloid plaque burden in mice 
[10,15-18,23]. These results have made the γ-secretase 
complex one of the top targets for developing AD 
therapeutics. Here we show that the novel Aβ isoforms 
Aβ1-14, Aβ1-15, and Aβ1-16, together with Aβ1-34, may 
serve as sensitive biomarkers for γ-secretase inhibition by 
LY450139 in the CNS of AD patients.
In a previous study using ELISA measurements of CSF 
Aβ1-40 and Aβ1-42, the expected reduction of the 
peptides in response to LY450139 treatment was not 
found [19]. It was suggested that this lack of changes 
might be the result of a rapid transport of Aβ from CSF 
into plasma or that longer treatment duration may be 
required to identify changes [19]. In another study using 
the SILK method to examine whether an effect on Aβ 
production could be identified with LY450139 treatment, 
it was shown that Aβ production in the CNS decreased 
while Aβ clearance remained stable [21]. The lack of 
effect on CSF Aβ1-40 and Aβ1-42, despite the reduced 
Aβ production, may be because the different techniques 
are measuring different targets. SILK analysis of Aβ 
turnover requires that all Aβ isoforms are digested with 
trypsin before analysis, and a cleavage product consisting 
of Aβ17-28 is then measured by using MS [20]. Thus, 
total Aβ (that is, the mean of all of the very different Aβ 
isoforms that contain the Aβ17-28 sequence) is measured. 
This means that all longer isoforms detected in the 
present study (Aβ1-33, Aβ1-34, Aβ1-37, Aβ1-38, Aβ1-40, 
and Aβ1-42) will contribute to the mass spectrometric 
signal. The results presented herein suggest that the reduc-
tion in Aβ1-34, the generation of which is γ-secretase 
dependent [10-11,27], may contribute to the overall 
reduction of Aβ detected in CSF by using the SILK 
method.
Previous experimental studies on certain cultured cells 
expressing wild-type human APP have shown that γ-
secretase inhibitor can increase in α- and β-secretase 
cleavage products along with the expected increase in 
APP C-terminal fragments (C99 APP-CTF) [28]. Further, 
recent data have shown that the levels of Aβ1-14, Aβ1-15, 
and Aβ1-16 are elevated in cell media and CSF from 
transgenic mice treated with γ-secretase inhibitors and 
that these shorter isoforms are derived from concerted 
cleavages of APP by β- and α-secretase, thus reflecting a 
third metabolic pathway for APP [23,24]. Data in this 
study suggest that these shorter Aβ isoforms may be 
sensitive novel biomarkers for γ-secretase inhibitor 
treatment, even at doses that do no affect the CSF levels 
of Aβ1-40 or Aβ1-42. The increased levels of the isoforms 
detected after γ-secretase inhibitor treatment might be 
explained by an increased amount of substrate (that is, 
Figure 3. Representative mass spectra. (a) Representative mass 
spectra from an AD patient displaying the Aβ-isoform pattern before 
treatment (red spectra) and after treatment with 140 mg of the 
γ-secretase inhibitor LY450139 (blue spectra). The mass spectrometric 
signal of Aβ1-14/15/16 increased, whereas Aβ1-34 decreased. 
The longer isoforms, including Aβ1-17, Aβ1-40, and Aβ1-42, were 
unaffected by the treatment. The relative change as a response to 
treatment is displayed for (b) all Aβ isoforms detected in all samples 
and (c) α-sAPP and β-sAPP. The error bars represent standard errors 
of the mean.
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β-CTF or C99) (Figure 1), for α-secretase, after APP is 
cleaved by β-secretase.
Here we verify these findings directly in living AD 
patients (that is, a major increase of the shorter isoforms 
and a slight increase of α-sAPP, in CSF from AD patients 
treated with a γ-secretase inhibitor). The unchanged CSF 
levels of Aβ1-40 and Aβ1-42 are in agreement with 
previous studies [19] and suggest that these markers are 
less sensitive to detect γ-secretase inhibition as compared 
with Aβ1-14, Aβ1-15, and Aβ1-16, possibly because they 
may be influenced by other factors, such as brain amyloid 
load and/or Aβ oligomerization or that they are present 
at higher levels in CSF and that higher doses are needed 
to detect effects on these biomarkers in AD patients. 
Unchanged β-sAPP levels and only slightly elevated α-
sAPP levels suggest that γ-secretase inhibition does not 
result in any major change in the release of these APP 
fragments to the CSF. It is at this stage unclear whether 
these fragments are degraded further or if they simply are 
present in such high concentrations in the CSF that a 
very high γ-secretase inhibitor dose is needed to detect 
an effect on CSF α-sAPP and β-sAPP levels.
Conclusions
This study suggests that Aβ1-14, Aβ1-15, and Aβ1-16 are 
positive and very sensitive biomarkers for γ-secretase 
inhibition and can be used to detect biochemical effects on 
APP processing in AD patients treated with LY450139. 
Long-term clinical trials are needed to reveal whether these 
biomarkers predict a beneficial clinical treatment effect.
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